107 related articles for article (PubMed ID: 12145687)
21. Surface expression of hemopoietic cell phosphatase fails to complement CD45 deficiency and inhibits TCR-mediated signal transduction in a Jurkat T cell clone.
Musci MA; Beaves SL; Ross SE; Yi T; Koretzky GA
J Immunol; 1997 Feb; 158(4):1565-71. PubMed ID: 9029091
[TBL] [Abstract][Full Text] [Related]
22. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
[TBL] [Abstract][Full Text] [Related]
23. B cell antigen receptor (BCR)-mediated formation of a SHP-2-pp120 complex and its inhibition by Fc gamma RIIB1-BCR coligation.
Nakamura K; Cambier JC
J Immunol; 1998 Jul; 161(2):684-91. PubMed ID: 9670943
[TBL] [Abstract][Full Text] [Related]
24. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
25. Involvement of SHP-2 in multiple aspects of IL-2 signaling: evidence for a positive regulatory role.
Gadina M; Stancato LM; Bacon CM; Larner AC; O'Shea JJ
J Immunol; 1998 May; 160(10):4657-61. PubMed ID: 9590209
[TBL] [Abstract][Full Text] [Related]
26. Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4.
Showe LC; Fox FE; Williams D; Au K; Niu Z; Rook AH
J Immunol; 1999 Oct; 163(7):4073-9. PubMed ID: 10491012
[TBL] [Abstract][Full Text] [Related]
27. src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation.
Kamata T; Yamashita M; Kimura M; Murata K; Inami M; Shimizu C; Sugaya K; Wang CR; Taniguchi M; Nakayama T
J Clin Invest; 2003 Jan; 111(1):109-19. PubMed ID: 12511594
[TBL] [Abstract][Full Text] [Related]
28. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling.
Yu WM; Hawley TS; Hawley RG; Qu CK
Oncogene; 2003 Sep; 22(38):5995-6004. PubMed ID: 12955078
[TBL] [Abstract][Full Text] [Related]
29. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas.
Kolenko V; Wang Q; Riedy MC; O'Shea J; Ritz J; Cathcart MK; Rayman P; Tubbs R; Edinger M; Novick A; Bukowski R; Finke J
J Immunol; 1997 Sep; 159(6):3057-67. PubMed ID: 9300731
[TBL] [Abstract][Full Text] [Related]
30. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI
Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409
[TBL] [Abstract][Full Text] [Related]
31. Regulation of interleukin-3-induced substrate phosphorylation and cell survival by SHP-2 (Src-homology protein tyrosine phosphatase 2).
Wheadon H; Edmead C; Welham MJ
Biochem J; 2003 Nov; 376(Pt 1):147-57. PubMed ID: 12935294
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
Bousquet C; Susini C; Melmed S
J Clin Invest; 1999 Nov; 104(9):1277-85. PubMed ID: 10545526
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression.
Reichert TE; Nagashima S; Kashii Y; Stanson J; Gao G; Dou QP; Whiteside TL
Oncogene; 2000 Jan; 19(4):514-25. PubMed ID: 10698521
[TBL] [Abstract][Full Text] [Related]
34. Negative autoregulation of Src homology region 2-domain-containing phosphatase-1 in rat basophilic leukemia-2H3 cells.
Ozawa T; Nakata K; Mizuno K; Yakura H
Int Immunol; 2007 Sep; 19(9):1049-61. PubMed ID: 17675340
[TBL] [Abstract][Full Text] [Related]
35. Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
McKenzie RC; Jones CL; Tosi I; Caesar JA; Whittaker SJ; Mitchell TJ
Leukemia; 2012 Feb; 26(2):323-31. PubMed ID: 21818116
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine phosphatase SHP-2 dephosphorylates the platelet-derived growth factor receptor but enhances its downstream signalling.
Zhao R; Zhao ZJ
Biochem J; 1999 Feb; 338 ( Pt 1)(Pt 1):35-9. PubMed ID: 9931295
[TBL] [Abstract][Full Text] [Related]
37. Effects of SOV-induced phosphatase inhibition and expression of protein tyrosine phosphatases in rat corneal endothelial cells.
Chen WL; Harris DL; Joyce NC
Exp Eye Res; 2005 Nov; 81(5):570-80. PubMed ID: 15950220
[TBL] [Abstract][Full Text] [Related]
38. Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1.
Maeda A; Scharenberg AM; Tsukada S; Bolen JB; Kinet JP; Kurosaki T
Oncogene; 1999 Apr; 18(14):2291-7. PubMed ID: 10327049
[TBL] [Abstract][Full Text] [Related]
39. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154.
Säemann MD; Zeyda M; Diakos C; Szekeres A; Böhmig GA; Kelemen P; Parolini O; Stockinger H; Prieschl EE; Stulnig TM; Baumruker T; Zlabinger GJ
Transplantation; 2003 Jun; 75(11):1864-72. PubMed ID: 12811247
[TBL] [Abstract][Full Text] [Related]
40. The tyrosine phosphatase SHP-2 regulates differentiation and apoptosis of individual primary T lymphocytes.
Hoff H; Brunner-Weinzierl MC
Eur J Immunol; 2007 Apr; 37(4):1072-86. PubMed ID: 17330819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
